SMNP + PD-1 inhibitor

SMNP + PD-1 inhibitor refers to an investigational immuno-oncology combination regimen in which a saponin-based molecular nanoparticle (SMNP) adjuvant is administered together with a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor to enhance adaptive antitumor or vaccine-elicited immunity. SMNP is a particulate saponin adjuvant designed to strongly stimulate innate immune pathways in draining lymph nodes and promote robust CD4+ and CD8+ T‑cell and antibody responses, while PD-1 inhibitors such as pembrolizumab or nivolumab block the PD-1 checkpoint on T cells to prevent exhaustion and restore effector function against tumor cells. Together, the combination is intended to amplify T‑cell priming and effector activity beyond that achieved with PD-1 blockade alone, potentially improving depth and durability of responses in cancer immunotherapy or therapeutic vaccination settings.